US gets lower return on its cancer drug spending, study findsBMJ 2016; 353 doi: http://dx.doi.org/10.1136/bmj.i2494 (Published 03 May 2016) Cite this as: BMJ 2016;353:i2494
- Michael McCarthy
Increased spending on cancer drugs has yielded significant benefits in terms of years of life gained, but compared with other developed nations the United States has seen the smallest return on its investment, a new study has found.1
Researchers compared changes in spending on cancer drugs and changes in years of potential life lost due to neoplasms from 2004 to 2014 in Australia, Canada, France, Germany, Italy, Japan, Sweden, the United Kingdom, and the United States.
“All nine countries—most notably France and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial